加载中
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
收盘时
US$36.415
−US$1.145 · -3.05%
盘后
US$36.415
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日内区间
当前US$36.415
52周区间
当前US$36.415
盘中时间采用ET。市场数据可能有所延迟。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日内区间
当前US$36.415
52周区间
当前US$36.415
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|
| 营收 | 4595.1万 USD | 107.5万 USD | 15.1万 USD |
| 毛利 | 4595.1万 USD | 107.5万 USD | 15.1万 USD |
| 研究与开发 | 9758.4万 USD | 6533.7万 USD | 3597.9万 USD |
| 销售、一般及管理费用 | 2916.4万 USD | 1656.1万 USD | 972.2万 USD |
| 营业费用 | 1.27亿 USD | 8189.8万 USD | −192.4万 USD |
| 利息收入 | 1953万 USD | 861.7万 USD | 278.6万 USD |
| 折旧和摊销 | 160.4万 USD | 140.1万 USD | 84.8万 USD |
| 营业利润 | −8079.7万 USD | −8082.3万 USD | 207.5万 USD |
| 净利润 | −4887.9万 USD | −7179.8万 USD | 418万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$50.40
上涨空间 38.40%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3539.04万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM2137.32万0.03%787.4亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF1016.98万0.01%954亿 USD0.05%US$232.54-0.42%
State Street SPDR S&P Pharmaceuticals ETFXPH875.99万1.87%4.69亿 USD0.35%US$62.10-2.98%
iShares Biotechnology ETFIBB854.28万0.08%108.2亿 USD0.44%US$200.02-2.08%
First Trust Small Cap Growth AlphaDEX FundFYC831.49万0.61%13.49亿 USD0.70%US$114.19-0.57%
iShares Russell 2000 Growth ETFIWO505.75万0.04%139.17亿 USD0.24%US$351.1-0.74%
Vanguard Russell 2000 ETFVTWO485.18万0.03%180亿 USD0.06%US$111.77-0.45%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
